New Contrast Agent Enables Earlier Diagnosis in Parkinson's

June 19, 2013

When the contrast agent ioflupane I 123 with iodine (DaTscan, GE Healthcare) is used with single-photon emission computed tomography(SPECT) to diagnose early-stage Parkinson's disease, it performs as well as clinical assessment at 1-year follow-up, according to a new study.

The method could improve the diagnosis of early-stage disease and help ensure that patients get put on the right therapeutic regimen from the outset.